VINATIORGA Q4 FY26 earnings call.
A source-linked concall view: reported numbers, management language, guidance, commitments and risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹604 Cr
verified against source
Revenue YoY
—
reported change
EBITDA
₹203 Cr
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Vinati Organics delivered solid sequential improvement in Q4 FY26 with standalone revenue of 631 crores, EBITDA of 203 crores (up 20% QoQ), and PAT of 137 crores (up 27% QoQ). Full-year standalone EBITDA grew 17% to 741 crores while PAT rose 18% to 488 crores. The company completed ATBS capacity expansion and guided for approximately 15% volume growth at company level in FY27, with ATBS specifically targeting 15-20% growth over the next 3 years. Capex guidance stands at 200-250 crores for FY27 with VOPL subsidiary expected to contribute from Q3 FY27 post re-engineering. Management flagged Chinese competition in antioxidants and ADD application uncertainty as key headwinds. The company remains debt-free with 190 crores in treasury. Key risks include delayed VOPL ramp-up, ADD rejection reapplication outcome, and ongoing raw material price volatility amid geopolitical tensions.
Colored figures show movement against the previous available record.
Guidance to track
- Company targets approximately 15% volume growth at the consolidated level for FY27, driven by recovery in ATBS demand and steady performance across other segments.
- Phase 1 expansion completed; expecting 15-20% volume growth in ATBS for FY27 with double-digit annual growth projected for next 3 years to absorb expanded capacity.
- Earmarked approximately 200-250 crores for FY27, including 40-50 crores for VOPL subsidiary and remainder for value-added products (derivatives of MEHQ, butyl phenols, antioxidants).
- 100% subsidiary VOPL undergoing process re-engineering expected to complete by September with revenue contribution anticipated from Q3 FY27 onwards (~20 crores).
- Management maintains that 26-27% EBITDA margin is reasonably achievable on a long-term basis given expansions, new products, and raw material fluctuations.
Risks flagged
- Previous ADD application was rejected with ~80-90% of applications rejected. Company has reapplied but outcome expected in 6-9 months with no guarantee of approval.
- New process at VOPL subsidiary faced teething troubles requiring re-engineering. While management expects completion by September, any further delays could impact FY27 revenue guidance.
- Chinese competitors are undercutting aggressively in antioxidants, preventing the company from achieving anticipated growth despite 50-55% capacity utilization. Management acknowledged missing growth targets.
- ATBS growth linked to butyl phenol supply; current utilization at 70-75% with limited space for capacity increase. Any demand surge would prioritize captive consumption over external sales.
Key quotes
- I think I've maintained an ebida margin of 26 to 27% because you know given expansions, new products, raw material fluctuations, I think that's a reasonably achievable eida margin on a long-term basis.
- The sector has seen a lot of cyclicality in the last few years. Cycles have shortened. People overreact, demand supply, suddenly customers panic and they want to buy a lot and then suddenly they realize they have overstock.
- Isoylene derivatives have been dropped as of now, we are not pursuing. Tertiary am alcohol as well as MAP we will produce. I have not heard of any customer backward integrating.
Research modules